Abivax stock surges 30 percent on reassuring obefazimod safety data
Abivax stock climbed more than 30% after the French biotech released additional data from its late-stage trial of obefazimod, showing that cancer cases in the study were consistent with background rates expected in that patient population.

_1431005_640x360_2505180739889-640x360.webp&w=3840&q=75)
_1430991_640x360_2505182787546-640x360.webp&w=3840&q=75)
_1430983_640x360_2505182787549-640x360.webp&w=3840&q=75)




_1430955_640x360_2505173571533-640x360.webp&w=3840&q=75)


_1430933_640x360_2505175619555-640x360.webp&w=3840&q=75)